239 filings
8-K
SNGX
Soligenix Inc
22 Apr 24
Soligenix Announces Pricing of $4.75 Million Public Offering
4:05pm
8-K
SNGX
Soligenix Inc
3 Apr 24
Randomized Study with 18 Weeks Continuous Treatment Expected to Replicate and Extend Results from the First, Statistically Significant Phase 3 Study
4:05pm
8-K
SNGX
Soligenix Inc
22 Dec 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:05pm
8-K
SNGX
Soligenix Inc
15 Dec 23
Submission of Matters to a Vote of Security Holders
4:03pm
8-K
SNGX
Soligenix Inc
17 Nov 23
Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting
4:05pm
8-K
6xufoqla47jfomq
20 Oct 23
Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting
4:05pm
8-K
6dp9m9yko3mnp
22 Sep 23
Submission of Matters to a Vote of Security Holders
4:05pm
8-K
d1wg0bx4 tfao
15 Sep 23
Changes in Registrant's Certifying Accountant
4:05pm
8-K
2iia8f84va muov8n
7 Jul 23
Departure of Directors or Certain Officers
4:05pm
8-K
xwvjvz 41xwj
23 Jun 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:05pm
8-K
ayaj8ut
26 May 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:15pm
8-K
9eifh
9 May 23
Soligenix Announces Pricing of $8.5 Million Public Offering
4:15pm
8-K
54w 1glm5xvnf
3 May 23
Strengthens regulatory and orphan drug development expertise
5:00pm
8-K
ziz08ctw
1 May 23
Soligenix Enters into Exclusive Option Agreement with Silk Road Therapeutics for Rights to Topical Pentoxifylline Designed to Treat Behçet’s Disease
7:45am
8-K
khy8np1n4mmk013wvi
19 Apr 23
Entry into a Material Definitive Agreement
5:25pm
8-K
zmdfk 5n9
14 Apr 23
Other Events
8:33am
8-K
w99uthh50q56n353pce8
10 Apr 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
7:30am
8-K
cfgb va5f5
24 Feb 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:06pm
8-K
r55ti1cum6jd9q
14 Feb 23
Soligenix Receives Refusal to File Letter from U.S. FDA for HyBryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma
7:46am
8-K
sf2r7vqzaz 037aboug0
9 Feb 23
Soligenix Announces Reverse Stock Split
7:45am